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Interleukin-1βIn this study the role of P2Y12 receptors (P2Y12R)was explored in rodentmodels of inﬂammatory and neuropath-
ic pain and in acute thermal nociception. In correlation with their activity to block the recombinant human
P2Y12R, the majority of P2Y12R antagonists alleviated mechanical hyperalgesia dose-dependently, following
intraplantar CFA injection, and after partial ligation of the sciatic nerve in rats. They also caused an increase in
thermal nociceptive threshold in the hot plate test. Among the six P2Y12R antagonists evaluated in the pain stud-
ies, the selective P2Y12 receptor antagonist PSB-0739 was most potent upon intrathecal application.
P2Y12R mRNA and IL-1β protein were time-dependently overexpressed in the rat hind paw and lumbar spinal
cord following intraplantar CFA injection. This was accompanied by the upregulation of TNF-α, IL-6 and IL-10
in the hind paw. PSB-0739 (0.3 mg/kg i.t.) attenuated CFA-induced expression of cytokines in the hind paw
and of IL-1β in the spinal cord. Subdiaphragmatic vagotomy and the α7 nicotinic acetylcholine receptor antago-
nist MLA occluded the effect of PSB-0739 (i.t.) on pain behavior and peripheral cytokine induction. Denervation
of sympathetic nerves by 6-OHDA pretreatment did not affect the action of PSB-0739. PSB-0739, in an analgesic
dose, did not inﬂuence motor coordination and platelet aggregation. Genetic deletion of the P2Y12R in mice
reproduced the effect of P2Y12R antagonists on mechanical hyperalgesia in inﬂammatory and neuropathic pain
models, on acute thermal nociception and on the induction of spinal IL-1β.
Here we report the robust involvement of the P2Y12R in inﬂammatory pain. The anti-hyperalgesic effect of
P2Y12R antagonism could be mediated by the inhibition of both central and peripheral cytokine production
and involves α7-receptor mediated efferent pathways.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Purine nucleotides activating P2X and P2Y receptors are key extra-
cellular modulators of different forms of pain (Burnstock et al., 2011;
Koles et al., 2011). P2X receptors are ligand-gated non-selective cation
channels, forming trimeric co-assemblies of seven individual subunits
(P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7), whereas P2Y recep-
tors belong to the G protein-coupled metabotropic receptor family
consisting of eight different subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11,
P2Y12, P2Y13, P2Y14) (Coddou et al., 2011; von Kügelgen and Harden,
2011). Both P2X and P2Y receptors are expressed along nociceptive
pathways and rapidly accumulating data support their involvement in
the processing of pathological pain (Trang and Salter, 2012; Tsuda
et al., 2012). Whereas P2X3, P2X4, and P2X7 antagonists are currentlythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(Gum et al., 2012; Jarvis, 2010), among P2Y receptors, the P2Y12 recep-
tor (Hollopeter et al., 2001) has only recently been implicated in the
generation of pathological pain (Trang et al., 2012). P2Y12R antagonists,
such as clopidogrel, are widely used as safe drugs for the prevention of
myocardial infarction and stroke and have been among the world's
best selling drugs in the recent years (Debnath et al., 2010; Raju et al.,
2008). Accordingly, P2Y12Rs are highly expressed on platelets and
their activation by ADP results in rapid thrombocyte aggregation. How-
ever, P2Y12Rs are also expressed in the CNS, in particular in microglia
(Haynes et al., 2006). P2Y12R mRNA is upregulated in microglia and
the putative P2Y12R antagonist MRS2395 and a P2Y12R speciﬁc anti-
sense oligonucleotide inhibited hyperalgesia after partial sciatic nerve
ligation (PSNL, Seltzer model) in rats (Kobayashi et al., 2008). These re-
sults were then conﬁrmed using another P2Y12R antagonist, cangrelor
(AR-C69931MX), and by genetic invalidation of P2Y12R (Tozaki-Saitoh
et al., 2008). We have recently found that MRS2395 attenuated not
only neuropathic, but also inﬂammatory pain and acute thermal
nociception (Ando et al., 2010). The above studies strongly indicated
the participation of P2Y12Rs in different pain modalities. However, be-
sides P2Y12R, other metabotropic P2 receptors, such as P2Y6 and P2Y14
may also play a role in the modulation of neuropathic pain (Kobayashi
et al., 2012). Antagonists of P2Y receptors used in previous studies,
however, were not selective enough to obtain conclusive evidence for
the inhibition of P2Y12R as a new approach for inﬂammatory analgesia.
Moreover, themechanism of such an action has also remained enigmat-
ic until now.
In this study we have systematically examined the effect of genetic
deletion and different P2Y12R antagonists, including the selective
P2Y12R antagonist PSB-0739 (Baqi et al., 2009; Hoffmann et al., 2009)
on inﬂammatory and neuropathic pain and acute thermal nociception
in parallel with their in vitro efﬁcacy to inhibit the human recombinant
P2Y12R. Our data show that both genetic ablation and pharmacological
blockade of P2Y12R reduce pain in all three models. As a potential un-
derlying mechanism of these effects, we demonstrate the alleviation
of cytokine production in the spinal cord and in the inﬂamed paw
after central PSB-0739 treatment and the participation of α7 nAChRs
inmediating this effect. Ourﬁndings indicate that central P2Y12R inhibi-
tion is a plausible strategy to combat inﬂammatory and neuropathic
pain.
Materials and methods
Animals
All studies were conducted in strict accordance with the principles
and procedures outlined in Guide for the Care andUse of Laboratory An-
imals of the National Institutes of Health and followed the ARRIVE
guidelines. The local Animal Care Committee of the IEM HAS approved
all experimental procedures (Permission No: 22.1/3671/003/2008). An-
imals were kept under standard laboratory conditions with food and
water ad libitum. All efforts were made to minimize animal suffering
and reduce the number of animals used. All the experiments were car-
ried out between 9:00 and 14:00 in the housing room of the animals.
Experiments were performed on male Wistar rats obtained from the
local animal house and on male wild-type (C57/Bl6) and P2Y12R deﬁ-
cient mice (P2ry12−/−) weighting 25–30 g. B6;129-P2ry12tm1Dgen/H
knockout mice (P2ry12−/−) were established by Deltagen Inc. (San
Matteo, CA, USA). Mutation was generated with the insertion of lacZ
and neo genes into the p2ry12 gene in an R1 ES cell. The chimeric
mousewas crossed into C57Bl6 background and reposited and archived
in EMMA (EM:02301). After rederivation of mice from frozen stocks,
mutants were additionally crossed with C57Bl6/J mice in the Medical
Gene Technology Unit of the IEM HAS. Heterozygous breeding pairs
were then crossed to generate homozygous knock-outs and littermate
controls.Mice thatwere homozygous for the targeted allelewere viable,fertile, normal in size and did not display any gross physical or behavior-
al abnormalities. Mice were phenotyped by physical examination,
necropsy, including body weight, body length and organ weight mea-
surements, histopathology, clinical chemistry, aging and behavior. Indi-
vidual homozygous or heterozygous mutant mice had only occasional
minor differences in observed physical features compared to wild-
type control mice. These ﬁndings are considered to represent individual
variability, background features occasionally seen in this strain of mice,
ﬁndings due to spontaneous disease, age-related ﬁndings, procedural
artifacts, and/or ﬁndings of nonspeciﬁc document etiology. However,
none of these differences was regarded as biologically signiﬁcant or ge-
notype related. For the complete phenotype data of the original mouse
see Deltagen Inc. (https://deltaone.deltagen.com). Genomic DNA was
isolated from mouse-tail biopsies and genotypes were identiﬁed by a
multiplex quantitative PCR. We have used a Neo gene speciﬁc Taqman
assay (Lifetech Mr00299300_cn) simultaneously with a general
Taqman assay for the endogenous Tert gene (Lifetech 4458369) (in a
multiplex reaction) to determine the numbers of unique Neo genes in
the genome.
The wild type and modiﬁed p2ry12 alleles were identiﬁed by PCR
analysis using 3 primers in a single reaction. Two of these primers
(GS(E) and GS(E,T)) recognize the 4th exon of the p2ry12 gene, up-
stream and downstream of the modiﬁed region, while the third
(NEO(T)) recognizes the NEO (neomycin) selection cassette, which
was inserted into themutant allele. By this PCR test all 3 different geno-
types (wild type (+/+), heterozygous (+/−) and knockout (−/−))
could be distinguished: the GS primers (E and E,T) amplify only the
wild type allele as an 541 bp fragment and the NEO(T) primer paired
with the GS(E,T) primer amplify only themutant allele as a 404 bp frag-
ment. The primer sequences were as follows:
GS(E) TTCTTAGTGATGCTAAACTGGGAGC,
Neo(T) GGGCCAGCTCATTCCTCCCACTCAT,
GS(E,T) AGGGAATCCGTGCAAAGTGGAAGGG.
Measurement of mechanical sensitivity and inﬂammatory edema in
CFA-induced inﬂammatory pain model
In this set of experiments peripheral inﬂammationwas inducedwith
CFA and the mechanical sensitivity of the hind paws was measured
using a regularly calibrated electronic von Frey apparatus (Dynamic
plantar esthesiometer, Ugo Basile Instruments Model 37400; Stoelting,
Wood Dale, IL, USA) on each animal before and after CFA treatment as
previously described (Andó et al., 2010). The extent of edema was also
evaluated by measuring paw volumes using a plethysmometer (Ugo
Basile 7140, Stoelting, Wood Dale, IL, USA).
Brieﬂy, after consecutively submitting the animals (maleWistar rats,
150–250 g, 6–8/group) to both tests for baselinemeasurements, freshly
prepared CFA (0.1 ml, 50% in saline, Sigma-Aldrich, F5881) was injected
intradermally into the plantar surface of the right hind paw. 48 h after
treatment with CFA, the extent of edema and mechanical sensitivity
were measured on both hind paws. Animals were then treated with
P2Y12R ligands or vehicle and post-drug measurements were carried
out 15 or 30 min later.
Animals were subjected to intraperitoneal or intrathecal injections
of several doses of the following P2Y12R antagonists: MRS2395 (0.03–
1 mg/kg), clopidogrel (1–60 mg/kg), ticlopidine (3–100 mg/kg),
cangrelor (0.1–3 mg/kg), PSB-0739 (0.01–1 mg/kg) or, reactive blue 2
(0.1–3 mg/kg). Each animal was injected only once. The doses of
drugs were chosen based on extrapolation from previous studies
(Marteau et al., 2003; Takasaki et al., 2001; Vasiljev et al., 2003). Intra-
thecal injection was performed following the method of Mestre et al.
(1994): this method enables the injection of a drug directly to the cen-
tral nervous systemwithout anesthesia and to avoid harm to the spinal
cord. Brieﬂy, the injections were performed by holding the animal in
one hand and inserting a 23 G1″ needle connected to a 250 μL Hamilton
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L6 vertebrae. A volume of 5 μL of PSB-0739 solution or saline was
injected in every case.
Mechanical sensitivity of the hind pawswasmeasured in the follow-
ing way: after being placed into the observation chamber and habituat-
ed for 10 min, the animals were submitted to 5 individual consecutive
measurements and the average was taken as the value for mechanical
sensitivity for the paw of each animal (paw withdrawal threshold,
PWT), expressed in grams.
In experiments using mice, animals were lightly anesthetized with
isoﬂurane and received 30 μL of CFA subcutaneously in the plantar sur-
face of the right hind paw. PWTwasmeasured before and 48 h after the
intraplantar injection on both hind paws using a dynamic plantar von
Frey esthesiometer as described above.
Experimental neuropathy and measurement of mechanical hyperalgesia
In this set of experiments, male Wistar rats (150–250 g) or male
wild-type and P2ry12−/−mice (20–30 g) were submitted to partial li-
gation of the sciatic nerve, following the method of Seltzer et al. (Andó
and Sperlágh, 2013; Ando et al., 2010; Seltzer et al., 1990). Brieﬂy, ani-
mals were deeply anesthetized with ketamine and xylazine (50 mg/kg
i.p. each), and the sciatic nerve of one of the hind paws was exposed
at themid-thigh level. One-half to one-third of thenervewas then tight-
ly ligated with siliconized silk suture (rats: 7.0; mice: 9.0, Ethicon,
Johnson and Johnson, USA), the wound was closed with sutures and
the animals were allowed to recover. Before and 7 days after surgery,
mechanical sensitivity wasmeasured on both paws using the same pro-
cedure as described above. 7 days after surgery, most animals showed
an increased mechanical sensitivity of the operated paws as compared
to pre-surgery levels. Only those animals, which showed a minimum
of 30% change inmechanical sensitivitywere included in the study. Sub-
sequently, animals received intraperitoneal or intrathecal injections of
P2Y12R ligands or vehicle and post-drug measurements were carried
out 15 or 30 min later as described above.
Acute thermal nociception (hot plate test)
The effects of P2Y12R antagonists on acute thermal nociceptionwere
investigated using an increasing-temperature hot plate system (IITC Life
Science, Woodland Hills, CA, USA). This has an advantage over the con-
ventional (constant temperature) hot plate system, because no sensiti-
zation or desensitization occurs after repeated experiments, which
enables repeated testing on the same animal (Almasi et al., 2003).
In the experiments, male Wistar rats (weighing 150–250 g) or male
wild-type and P2ry12−/−mice (20–30 g) were used. On the day of test-
ing, animals were placed in the hot-plate apparatus and after a period of
habituation (ca. 10 min), the plate was heated from the starting temper-
ature of 25 °C with a constant rate of 6 °C/minute, until the animals
showed nocifensive behavior (frequent lifting and/or licking of the hind
paw). Heating was then instantly stopped, the animal was removed
from the cage and the plate rapidly cooled. The temperature at which
the animal showed any sign of nocifensive behavior was taken as PWT,
expressed in °C. 30min later, themeasurementwas repeated and the av-
erage of two valueswas taken as thebaseline thermal nociceptive thresh-
old. After the second measurement, the animals received treatments
with P2Y12R antagonists as described above and 15 or 30 min after
drug administrations, post-drug nociceptive threshold was measured.
Subdiaphragmatic vagotomy (VGX)
Subdiaphragmatic vagotomy was performed according to the
method described in Andrews et al. (1985). Brieﬂy, animals were anes-
thetizedwith ketamine and xylazine (50 mg/kg i.p. each) and a 3–4-cm
long midline incision was made on the ventral abdominal surface. The
liver was retracted to the animal's right, and the esophageal-stomaticjunctionwas located as a point of reference. The stomachand esophagus
were gently retracted caudally. The vagus nerve was explored and visu-
alized with the use of a surgical microscope. Both anterior and posterior
segments (approximately 1.5 cm in length) of the vagus nerve were re-
moved. Thewoundwas closed and animals received 10ml saline subcu-
taneously. Gentamicin was administered postsurgically (5 mg/kg for
5 days) and animals were separately housed for several days. All ani-
mals were monitored thoroughly during the postoperative period and
wounds were cleaned when necessary. Following recovery from sur-
gery, animals were group housed.
In order to measure the effect of subdiaphragmatic vagotomy on
pain behavior PWT was measured before operation as baseline and im-
mediately prior to intraplantar CFA injection on the tenth day after op-
eration. Freshly prepared Complete Freund Adjuvant (CFA, 100 μl, 50%,
Sigma) was then injected to the right hind paw of the animals intrader-
mally and PWT was measured two days after treatment. Animals then
received the selective P2Y12R antagonist PSB-0739 (0.3 mg/kg) or sa-
line intrathecally and PWT was measured again.
Analysis of cellular cyclic AMP accumulation
Changes in cellular cAMP levels were determined as described previ-
ously (Algaier et al., 2008; Hoffmann et al., 2008). Brieﬂy, CHO Flp-In
cells or 1321N1 astrocytoma cells stably expressing the recombinant
human P2Y12R or mock transfected cells were cultured on 24-well
plates. After removal of the culture medium, cells were incubated with
HBSS buffer at 36 °C. Cellular cAMP production was then accelerated
by the addition of 10 μM forskolin (CHO cells) or 10 nM isoprenaline (as-
trocytoma cells) for 10 min. Solvent (control) or 2-methylthio-ADP was
added together with forskolin or isoprenaline. When used, antagonists
were given 10 to 25min before the agonist 2-methylthio-ADP. The reac-
tionwas stopped after 10min by removal of the reaction buffer, followed
by the addition of a hot lysis solution. cAMP levels in the supernatant
were thenquantiﬁed by incubation of an aliquotwith cAMPbinding pro-
tein and [3H]-cAMP (Perkin Elmer, Rodgau, Germany) and liquid scintil-
lation counting after removal of the unbound [3H]-cAMP by charcoal.
cAMP levels per well were calculated by regression analysis from a stan-
dard curve determined for each experiment. Concentration-response
data were ﬁtted by non-linear regression using GraphPad Prism (4.03)
to estimate half-maximal concentrations. Apparent pKB-valueswere cal-
culated according to: pKB = log (dose ratio− 1)− log[B]. pA2-values
were determined by linear regression analysis.
In our previous studies (Algaier et al., 2008; Hoffmann et al., 2008)
mock transfected CHO-Flp-In cells as well as non-transfected CHO-Flp-
In cells failed to respond to the agonist 2-methylthio-ADP in inhibiting
cAMP levels or in a SRE-directed reporter gene assay expected with
the absence of functional P2Y12-receptors in these cells. qPCR analysis
of mRNA levels conﬁrmed this view. A probe designed to detect
mRNA encoding for rodent P2Y12-receptors (AGAACGAGGGGTTCAGCC
AAAGC; TGAATGGATCAAGGCAGGCGTTC) showed nodetectable signals
(Ct values N 33) either in non-transfected CHO-Flp-In cells or in CHO-
Flp-In cells stably expressing the human P2Y12-receptor. In contrast, a
probe designed to detect mRNA encoding the human P2Y12-receptor
(TCGACAACCTCACCTCTGCGC; CCTCATCGCCAGGCCATTTGTGA) showed
a Ct-value of 28.5 ± 0.2 (n = 3) in CHO cells expressing the recombi-
nant human P2Y12-receptor and no speciﬁc signals in non-transfected
CHO cells (Ct value of the house keeping gene GAPDH 25.3 ± 0.1;
Qiagen fast lane cell cDNA kit and Qiagen SYBR green PCRmix analyzed
on an Applied Biosystems StepOnePlus RT-PCR system with 40 cycles
consisting of 95° for 10 s and 60° for 30 s).
Measurement of the pro-inﬂammatory cytokine IL-1β
Animals were randomly assigned to experimental groups with 3–4
rats/mice in each group. All animalswere given an intraplantar injection
of sterile saline (0.9% NaCl) or CFA suspended in an oil/saline (1:1)
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mice: 30 μL) into the plantar surface of the right hind paw. The contra-
lateral left hind paw of the same animal received an identical volume of
saline. Mechanical hyperalgesia was measured on day 0 (i.e. prior to
intraplantar injection), 48 h and 96 h after intraplantar injection of
CFA or saline as described above. The selective P2Y12R antagonist PSB-
0739 (0.3 mg/kg) was injected i.t. 15 min before, while the non-pro-
drug-P2Y12 receptor antagonist cangrelor (3 mg/kg) was added i.p. 30
min before the post-CFA measurement of mechanical hyperalgesia.
After behavioral testing at 48 h or 96 h, rats were killed by decapitation.
These time points were chosen to represent acute (48 h) and subacute
(96 h) phases of inﬂammation (Parra et al., 2002). Samples of L4-L6
lumbar spinal cord (96 h) and hind paw (48 h) were collected, frozen
on dry ice/liquid nitrogen and stored at−70 °C until mRNA and protein
isolation. In a set of experiments, chemical sympathectomywas induced
by intraperitoneal injections of 6-OHDA dissolved in 0.1% ascorbic acid,
administered in every second day over 5 consecutive days (40 mg/kg,
60 mg/kg, 60 mg/kg) following the protocol described by Lorton et al.
(1999). The ﬁnal 6-OHDA treatments were followed by intraplantar
injection of CFA or saline as described above. After the experiment,
the monoamine content of the hind paws was analyzed by HPLC.
In other experiments, the α7 nACh receptor antagonist MLA or its
vehicle (saline) was administered 45 min prior to the post-CFA PWT
determination.
For the IL-1β assays, samples were homogenized in 500 μl 10 mM
Tris–HCl buffer containing 1 mM EGTA, 1 mM EDTA, 0.2 mM PMSF
and 4 M urea per 0.1 g tissue as described previously (Csolle and
Sperlagh, 2010). The initial tissueweightwas 80mg. Sampleswere cen-
trifuged at 4 °C for 20min at 15,000 g and the supernatantwas collected
in 500 μl 10 mM Tris–HCl buffer containing 1% BSA and 0.2% Tween 20.
Levels of IL-1β (both pro andmature) production were evaluated using
an ELISA kit, DuoSet IL-1β (R&D System,Minneapolis, MN, USA), specif-
ic for rat and mouse IL-1β protein, respectively, according to the
manufacturer's instructions. IL-1β levels were then calculated by plot-
ting the optical density (OD) of each sample (two-fold diluted) against
the standard curve. A seven point standard curve using two-fold serial
dilutions in Reagent Diluent (according the manufacturer's instruc-
tions), and high standard of 4000 pg/ml were used for the determina-
tion of IL-1β levels. Assay detection limits were b5 pg/ml. Absorbance
was measured at 450 nm, using a Perkin-Elmer Victor 3V 1420
Multilabel Counter. IL-1β level was expressed in pg/ml.
Quantitative real-time PCR experiments
Rats were treated as described for the IL-1β production assay, and
animals were killed by decapitation 48 h or 4 days following CFA or sa-
line injection. The hind paw and L4-L6 spinal cordwere collected, frozen
in liquid nitrogen and stored at−70 °C until homogenization. Total RNA
samples were isolated and puriﬁed from the cell lysates using the
RNeasy Lipid Tissue Mini Kit (Qiagen) according to the manufacturer's
instructions. RNA (2 μl) was reverse-transcribed with RevertAid First
Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania) as described
in our previous studies (Papp et al., 2004; Sperlagh et al., 2002). Brieﬂy,
the cDNA samples were prepared by reverse transcribing 1 μg of total
RNA using 1 μl of RevertAid H Minus M-MuLV reverse transcriptase in
a mixture containing 5 μl of 5× reaction buffer, 1 μl random hexamer
primer (10 pmol/μl), 1 μl of RiboLock™ RNase Inhibitor (20 u/μl), and
2 μl of 10 mM dNTP mix, which was brought up to a ﬁnal volume of
20 μl with 0.1% diethylpyrocarbonate-treated distilled water. The re-
verse transcription reaction was performed at 70 °C for 5 min, and syn-
thesis then continued at 25 °C for 15 min followed by 60 min at 42 °C
and the samples were ﬁnally stored at −20 °C. Expression levels of
the target genes were determined from the cDNA samples using quan-
titative real-time PCR (Rotor-Gene 3000; Corbett Research, Sydney,
Australia). Real-time PCR was performed according to standard proto-
cols using the LightCycler DNA Master SYBR Green I Kit (Roche,Indianapolis, IN, USA). PCR conditions were optimized for primers, tem-
plates, and MgCl2. The PCR cycling protocols were as follows: initial de-
naturation, 95 °C for 5min; cycling, 94 °C for 1min, 59 °C for 1min, 72 °C
for 5 min; 40 cycles. The following primers were used for P2Y12RmRNA
detection: P2Y12R forward primer, CAGGTTCTCTTCCCATTGCT; reverse
primer, CAGCAATGATGATGAAAACC; and 18S forward primer, 5′-GTAA
CCCGTTGAACCCCATT, reverse primer, 3′-CCATCCAATCGGTAGTAGCG.
Analysis of real-time PCR measurements
To ensure reaction speciﬁcity and accurate quantiﬁcation, melting
curve analysis was performed after each reaction, which conﬁrmed
the lack of primer–dimer artifacts or contamination in all cases. All
ΔCt values were calculated by the Rotor Gene 5 software (Corbett Re-
search, Sydney, Australia). Expression levels of the target genes were
normalized to the expression level of the reference gene, the house-
keeping gene 18S rRNA. The target gene and reference gene were mea-
sured together within the same experiment. To compare expression
level of target genes between the different experimental groups, the ef-
ﬁciency calibrated model of Pfafﬂ (2001) was applied. Differences in
gene expression levels between experimental groups were considered
signiﬁcant at P b 0.05. Data are presented as mean normalized expres-
sion ratio ± SEM.
Multiplex cytokine measurement
The quantiﬁcation of levels of pro-inﬂammatory cytokines TNF-α,
IL-1β and IL-6, and the anti-inﬂammatory cytokine IL-10 was per-
formed by Luminex xMAP platform assays. For the multiplex cytokine
assay, the spinal cord and hind paw were homogenized in 500 μl
10mM Tris–HCl buffer containing 1 mM EGTA, 1 mM EDTA, 0.2 mM
PMSF and 4 M urea per 0.1 g tissue. The samples were centrifuged at
4 °C for 20 min at 15,000g and the supernatant was collected in 500 μl
10 mM Tris–HCl buffer containing 1% BSA and 0.2% Tween 20. The
bead-based Multiplex cytokine proﬁling on hind paw and spinal cord
samples was performed in the Fluorescent Core Facility of the
Semmelweis University, Budapest. Fluorokine® Multianalyte Proﬁling
(MAP) Kits were used according to the manufacturer's instructions.
HPLC analysis
Concentrations of monoamines and their metabolites in the rat paw
tissuewere determinedwith HPLC using electrochemical detection. The
native tissue was homogenized by sonication in 300 μl 0.1 M ice-cold
perchloric acid which contained 10 mM theophylline as an internal
standard and antioxidant, 0.1% sodium metabisulﬁte. The protein pre-
cipitate was removed by centrifugation at 3510 g for 10 min at 4 °C
and determined according to Lowry et al. (1951). The excess of perchlo-
rate anion of supernatant was removed by the addition of 2 M KOH and
by centrifugation as described above. The liquid chromatographic sys-
temwas controlled by 715operation software (GilsonMedical Electron-
ics inc., Middletown, and WI USA) and consisted of solvent delivery
pumps, programmable injector for the automated column-switching
and an auto injector (SIL-10AD Shimadzu). The efﬂuent was connected
to a BAS 400 electrochemical cell which contained a glassy carbon elec-
trode versus Ag/AgCl reference electrode and the oxidizing potential
was maintained at 0.75 V by an Eltron potentiostat.
The online enrichment and stripping of samples were carried out on
a SUPELCOSIL LC-C18 (100 × 4.6mm I.D, 5 μmparticle sizes) column by
“RP” buffer (0.15 mM ammonium formate buffer, 0.25 mM EDTA, the
apparent pH was adjusted to 3.2). The separation was performed on
SUPELCOSIL LC-C18 DB (150 × 4.6 mm I.D., 3 μm particle size) column
by “RP” buffer with 0.6 ml/min ﬂow rate. The second part of analysis
was performed for 24 min with the “IP” buffer (0.15 mM ammonium
formate buffer, 0.25 mM EDTA, 0.45 mM octane sulphonic acid sodium
salt and 6% v/v acetonitrile, the apparent pH was adjusted to 3.2) and
the ﬂow rate increased to 0.98 ml/min. Concentrations were calculated
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data are expressed as pmol per mg protein.
Accelerating rotarod test
This study used 140–190 g drug- and test-naive male Wistar rats.
Motor coordination was tested on the IITC (Woodland Hills, CA, USA)
Rotarod Apparatus, which enables the simultaneous examination of
ﬁve rats. The apparatus consists of ﬁve compartments separated by
8 cm diameter rotating rod, placed 25 cm above the base of the appara-
tus. Motor coordination of animals was tested for 300 s with linear ac-
celeration from 5 rpm to 25 rpm. Rats were acclimatized to the
rotarod in three trials (300 s) per day for 2 consecutive days before
the start of the experiment. On the test day 30min prior to drug admin-
istration baseline latencies to fall were determined and rats with base-
line latencies less than 60 s were excluded from the study. The
animals were then treated with sterile saline or with antagonists intra-
peritoneally (3 mg/kg cangrelor/saline) or intrathecally (0.3 mg/kg
PSB-0739/saline). 30 min after the i.p. treatment or 15 min after i.t.
treatment the falling latency was measured again in the 300 s test
period. The latency time to fall off the rod was expressed in seconds.
Ex-vivo inhibition of platelet aggregation
This study used 200–250 g drug- and test-naive male Wistar rats.
The animals were treated with antagonists or with an equal volume of
sterile saline by intraperitoneal or intrathecal injection. 30 min after
i.p. treatment or 15 min after i.t. treatment animals were anesthetized
with an i.p. injection of ketamine (50 mg/kg)/xylazine (50 mg/kg),
and 3 ml of blood was drawn from the heart into Vacutainer tubes
and immediately mixed 1:10with an aqueous solution of trisodium cit-
rate (3.8%). Blood sampleswere centrifuged at 150 g for 8min. Then the
platelet-rich supernatant was carefully removed (platelet-rich plasma,
PRP). The remaining specimen was further centrifuged at 2500 g for
8 min to obtain platelet-poor plasma (PPP). Aliquots of 450 μl PRP or
PPP were placed in glass cuvettes and 50 μl of ADP (5 μM and 10 μM)
was added to the PRP to induce platelet aggregation. Measurements of
platelet aggregation were carried out using Carat TX-4 four channel
platelet aggregometer (Carat, Hungary) using the turbidimetricmethod
described by Born (1962). In order to eliminate individual differences,
the device stores light transmission of platelet-rich plasma and
platelet-poor plasma (PRP: 0%, PPP: 100%), and the induced aggregation
rate was calculated from the measured difference in optical density be-
tween PPP and PRP. The light transmission of the suspension increased
in parallel with the extent of aggregation, and this was displayed by the
built-in program connected to the device. From the resulting curve, the
maximal extent of aggregationwas considered, whichwas expressed as
percentage of maximal light transmission. During the 10-min measure-
ment, samples were incubated at 37 °C and continuously stirred at
1000 rpm. All measurements were carried out within 2 h after blood
sampling under validated conditions in the PentaCore Laboratory of
the Semmelweis University, Budapest, Hungary.
Drugs
The following drugs were used: cangrelor (TheMedicines Company,
Parsippany, NJ USA), clopidogrel hydrochloride (Sanoﬁ-Aventis, Buda-
pest Hungary), 6-OHDA, MLA, MRS2395, reactive blue 2 (all from
Sigma-Aldrich), morphine hydrochloride (TEVA, Gödöllő, Hungary),
ticlopidine hydrochloride (Tocris), suramin hexasodium salt (Bayer,
Wuppertal, Germany), and PSB-0739 (synthesized by Y. Baqi and C.E.
Müller, according to described procedures (Baqi and Müller, 2007,
2010; Baqi et al., 2009)). In in vitro experiments forskolin or isoprena-
line (both from Sigma-Aldrich) was used to accelerate cellular cAMP
formation and the effect of 2-methylthio-ADP trisodium salt (Sigma-
Aldrich) was examined. Drugs were dissolved in sterile saline or waterexcept MRS2395 and clopidogrel, which were dissolved in 25%
DMSO + 75% PEG as a stock solution, and forskolin was dissolved in a
mixture of DMSO + ethanol (1:7). Solutions were freshly prepared on
the day of use.
Statistics
All data were expressed asmeans ± S.E.M. of n observations, where
nmeans number of animals/well per group. For statistical comparison
of multiple treatment groups one-way ANOVA followed by Neuman–
Keuls (in vivo experiments) or Tukey (in vitro experiments) post-hoc
testwas used, andpost CFA-treatment PWTvalues (CFAmodel) or post-
operative PWT values of vehicle treated rats (Seltzer model) were com-
pared to values treated with drugs. The identical statistical method was
used for the multiplex cytokine measurement. For statistical analysis of
the hot plate test results, corresponding baseline and post-drug data
were compared using the paired t-test. For pairwise comparisons, the
unpaired t-testwas used, as appropriate.Mechanical hyperalgesia in ex-
periments performed on P2ry12−/−mice and their wild-type counter-
parts was analyzed by a repeated measures multivariate ANOVA to
identify pre-post treatment, genotype and ipsilateral–contralateral ef-
fects. In the case of the IL-β assay on mice, two-way ANOVA was used.
The Fischer LSD test was used for post-hoc comparison. Theminimal ef-
fective dose (mED)was determined as the lowest necessary dose to ob-
tain signiﬁcant change in the postoperative value/heat threshold as
compared to the vehicle treated/baseline controls. The maximal (Emax)
effect is deﬁned as the extent of maximal effect obtained in the dose-
range examined and is expressed in grams or °C, for mechanical and
thermal sensitivity, respectively.
Results
P2Y12R antagonists alleviate mechanical hyperalgesia in CFA-induced
inﬂammatory and neuropathic pain models and acute thermal nociception
in rats
The average value of baseline PWTwas 40.66 ± 0.38 g (n= 185) in
rats. 48 h after intraplantar CFA injection (0.1 ml, 50%), the PWT de-
creased to 20.12 ± 0.33 g (n = 185), indicating the development of
mechanical hyperalgesia. This change represented a statistically signiﬁ-
cant, 49%decrease (P b 0.001), compared to either the PWTvalues of ip-
silateral pre-CFA or the contralateral (38.80 + 0.43 g, n = 185) hind
paws (Fig. 1A). CFA treatment also caused edema in the treated hind
paw, the extent of volumetric increasewas 147%,whichwas signiﬁcant,
compared to either the pre-CFA values (pre: 1.76 ± 0.01 ml, n = 185,
and post: 2.6 ± 0.01 ml, n = 185, P b 0.001) or the contralateral values
(1.77 ± 0.009 ml, n = 185, P b 0.001) (Fig. 1B).
We examined six P2Y12R antagonists in different doses using the ex-
perimental protocol shown in Fig. 1A. Antagonists, or their vehicle, were
administered 48 h after CFA treatment, after the determination of post-
CFA treatment PWT values. After 30 min, the PWT values were mea-
sured again, and the values were compared to the respective post-CFA
treatment PWT values. We have evaluated the effect of clopidogrel
and ticlopidine, two pro-drug P2Y12R antagonists, widely used in clini-
cal practice; the effect of MRS2395 (compound 26 in Xu et al., 2002,
and also examined by Kobayashi et al., 2008), reactive blue 2, an antag-
onist acting at several subtypes of P2Y receptors, cangrelor, the non-
pro-drug P2Y12 receptor antagonist as well as PSB-0739, the selective
and potent P2Y12R antagonist (Baqi et al., 2009).
Intraperitoneal administration of saline or vehicle (DMSO:PEG =
1:3) did not affect signiﬁcantly the post-CFA treatment PWT values
(19.5 ± 1.22 g, n = 8, and 22.99 ± 2.16 g, n = 6, P N 0.05 vs. pre-
CFA). By contrast, all P2Y12R antagonists dose-dependently and signiﬁ-
cantly counteracted CFA-induced mechanical hyperalgesia (Figs. 1C, D,
Table 1). Clopidogrel exhibited a signiﬁcant effect in the range of
10–30 mg/kg and the mED value was 10 mg/kg (Fig. 1C). Ticlopidine
Fig. 1. Effects of P2Y12R antagonists in rat models of inﬂammatory, neuropathic and acute pain. A, B.Mechanical hyperalgesia (A) and edema (B) before (PRE) after (CFA) intraplantar CFA
injection in rats. CFA (100 μl, 50% in saline) was injected intradermally into the plantar surface of the right hind paw. 48 h after treatment with CFA, the extent of edema and mechanical
sensitivityweremeasured on both hind paws. Pawwithdrawal threshold values are presented in grams,whereas paw volume values are expressed inml (mean± S.E.M.). Injected (CFA),
but not control paws demonstrated a signiﬁcant, 49% decrease of pain threshold and 47% increase in paw volume. *** denotes statistical signiﬁcance of P b 0.001, Student t test. C, D. Effects
of clopidogrel (C) and PSB-0739 i.t. (D) on CFAmediated inﬂammatory pain behavior 48 h after injection in rats. The graphs show the PWT values in g corresponding to doses indicated on
the abscissa. Symbols indicate signiﬁcant differences from the pre-CFA treatment (**P b 0.01) and post-CFA treatment PWT values (##P b 0.01, ###P b 0.001), respectively. One-way
ANOVA followed by Neuman–Keuls post-hoc test, n = 6–12/group. E, F. Effects of clopidogrel (E) and PSB-0739 i.t. (F) on neuropathic pain behavior in rats. PWT values were assessed
onoperated (white triangles) and contralateral hind paws (black triangles) expressed in g. Asterisks indicate signiﬁcant differences from the postoperative values of saline (SAL) or vehicle
(VEH) treated animals (*P b 0.05, **P b 0.01, ***P b 0.001). One-way ANOVA followed by Neuman–Keuls post-hoc test, n = 6–12/group. G, H. Effects of clopidogrel (G) and PSB-0739 i.t.
(H) on acute thermal nociception in rats. Y axis values show the change in nocifensive threshold (ΔPWT, °C). Animals were treated with P2Y12 receptor antagonists in doses indicated on
the abscissa. Asterisks indicate signiﬁcant analgesic effect, compared to the pre-treatment values, *P b 0.05, **P b 0.01, paired t-test.
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(Table 1). MRS2395 had a dose-dependent analgesic effect in the
range of 0.1–1 mg/kg, and the greatest increase of PWT was observedat 1 mg/kg, which was signiﬁcantly different from the postoperative
threshold (Table 1). Reactive blue 2 had a moderate but signiﬁcant ef-
fect on mechanical hyperalgesia following CFA treatment. The mED
Table 1
Effect P2Y12 receptor antagonists on mechanical hyperalgesia in inﬂammatory (CFA) and
neuropathic (Seltzer) pain model as well as on acute thermal nociception.
Drug Dose
(mg/kg)
CFA Seltzer Hot plate test
ΔPWT (g) ΔPWT (g) ΔPWT (°C)
PRE 40.66 ± 0.38 41.20 ± 0.37 n.d.
POST 20.12 ± 0.33*** 18.48 ± 0.28*** n.d.
VEH i.p. 22.99 ± 2.16 17.13 ± 1.23 0.39 ± 0.32
SAL i.p. 19.5 ± 1.22 18.98 ± 1.71 −0.71 ± 0.45
SAL i.t. 21.08 ± 1.92 17.20 ± 1.08 n.d.
MRS2395 0.03 23.47 ± 2.32 17.27 ± 1.48 −0.36 ± 0.34
0.1 19.58 ± 2.64 12.87 ± 0.7 1.33 ± 0.52
0.3 22.65 ± 2.45 22.12 ± 0.76## 1.51 ± 0.19**
1 27.82 ± 2.63# 23.3 ± 1.4### 2.06 ± 0.40**
(±)Clopidogrel 0.3 n.d. n.d. 0.60 ± 0.45
1 21.72 ± 1.74 22.03 ± 0.77 1.05 ± 0.34*
3 23.88 ± 1.94 24.01 ± 1.52## 1.34 ± 0.39*
10 28.43 ± 1.40## 23.65 ± 1.33# 1.31 ± 0.48*
30 29.32 ± 1.53## 28.10 ± 1.33### n.d.
60 n.d. 27.04 ± 0.61### n.d.
Ticlopidine 3 24.58 ± 2.19# 22.99 ± 1.63 0.23 ± 0.55
10 28.15 ± 2.73### 23.93 ± 0.85 0.65 ± 0.18*
30 25.45 ± 2.18# 28.17 ± 1.72### 0.50 ± 0.19
60 33.02 ± 1.45### n.d. 1.34 ± 0.46*
100 32.33 ± 3.97### 37.02 ± 3.04### 2.69 ± 0.58**
PSB-0739 i.t. 0.01 20.51 ± 1.39 13.99 ± 1.20 1.84 ± 0.52*
0.03 20.99 ± 1.75 18.23 ± 1.78 1.61 ± 0.37*
0.1 25.00 ± 1.10## 21.91 ± 1.80### 1.47 ± 0.53*
0.3 29.25 ± 2.53### 20.53 ± 1.36## 1.48 ± 0.27**
1 n.d. 19.49 ± 1.06# n.d.
Cangrelor 0.1 29.25 ± 1.09### 23.77 ± 1.38## 0.96 ± 0.47
0.3 26.86 ± 2.39 21.67 ± 1.22 0.74 ± 0.34
0.6 27.07 ± 1.22# 25.72 ± 1.31### 0.27 ± 0.95
1 32.63 ± 2.19### 23.10 ± 2.03# 1.48 ± 0.85
3 n.d. 25.34 ± 1.91### n.d.
Reactive blue 2 0.1 21.50 ± 0.95 16.57 ± 0.38 n.d.
0.3 19.17 ± 1.97 17.98 ± 1.21 0.35 ± 0.56
0.6 26.68 ± 0.82## n.d. n.d.
1 26.00 ± 0.97## 15.37 ± 2.00 0.58 ± 0.43
3 18.22 ± 0.79 16.15 ± 0.93 −0.73 ± 0.42
60 n.d. n.d. 0.0001 ± 0.43
In CFA experiments symbols indicate signiﬁcant differences from the pre-CFA treatment
(***P b 0.01) and post-CFA treatment PWT values (##P b 0.01, ###P b 0.001), respective-
ly. One-wayANOVA followed byNeuman–Keuls post-hoc test, n = 6–12/group. In Seltzer
experiments symbols indicate signiﬁcant differences from the pre-CFA treatment
(***P b 0.01) and from the postoperative values of saline (SAL) or vehicle (VEH) treated
animals (#P b 0.05, ##P b 0.01, ###P b 0.001). One-way ANOVA followed by Neuman–
Keuls post-hoc test, n = 6–12/group. In hot plate tests asterisks indicate signiﬁcant anal-
gesic effect, compared to the pre-treatment values, *P b 0.05, **P b 0.01, paired t-test.
n.d. = not determined.
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could not detect signiﬁcant effects. Cangrelor had signiﬁcant analgesic
effect in the tested range of 0.1–1 mg/kg (Table 1). The mED value
was 0.1 mg/kg and the greatest effect was detected at 1 mg/kg
(Table 1). Based on its highly polar chemical structure, we have as-
sumed that PSB-0739, the selective and potent P2Y12R antagonist,
does not penetrate the blood–brain barrier. Indeed, preliminary experi-
ments revealed that it was without effect using intraperitoneal applica-
tion in either pain models (data not shown). Therefore in the following
experiments, we applied PSB-0739 intrathecally, which had dose-
dependent and signiﬁcant antihyperalgesic effect in low doses
(Fig. 1D, Table 1). The minimal effective dose was 0.1 mg/kg. We
found the greatest efﬁcacy on nocifensive threshold at 0.3 mg/kg,
whereas intrathecal injection of identical volume of saline did not
elicit any effect (Table 1). The rank order of mED values in these exper-
iments was the following: PSB-0739 i.t. = cangrelor N reactive blue
2 N MRS2395 N ticlopidine N clopidogrel. Of the compounds investi-
gated, only ticlopidine counteracted paw edema (data not shown).
Using the Seltzer model of neuropathic pain in rats, following the
protocol used in our previous studies (Ando et al., 2010), thepreoperative PWT was 41.20 ± 0.37 g (n = 151). Partial ligation
of the sciatic nerve decreased this value to 18.48 ± 0.28 g on the 7th
postoperative day (Table 1), representing a 55% decrease (n = 151,
P b 0.001) compared to either the preoperative value of the ipsilateral
hind paw or the value of the contralateral hind paw (41.72 ± 034 g,
n = 151).
We measured the effects of P2Y12R antagonists on mechanic
hyperalgesia on the 7th day after partial sciatic nerve ligation. PWT
values, determined 30 min after drug administration were compared
to the postoperative PWT values of the vehicle or saline treated animals.
PWT was also measured on the contralateral hind paw, however, none
of the treatments signiﬁcantly affected these values (e.g. Figs. 1E, F). In
this test, all P2Y12R antagonists investigated had signiﬁcant and dose-
dependent antihyperalgesic effects except reactive blue 2 (Table 1).
Clopidogrel had signiﬁcant analgesic effects in the 1–60 mg/kg dose
range, and the maximal effect was obtained at 30 mg/kg (Fig. 1E).
Ticlopidine also had a dose-dependent effect: the mED was 30 mg/kg
and at 100 mg/kg almost complete reversal of the hyperalgesia was ob-
served (Table 1). Similar to the results obtained in the inﬂammatory
pain model, MRS2395 had a dose-dependent analgesic effects in the
range of 0.1–1 mg/kg and the mED value was 0.3 mg/kg (Table 1).
Reactive blue 2 remained ineffective in this test in the dose-range of
0.1–3 mg/kg (Table 1). Cangrelor had a signiﬁcant effect on the pain
threshold at 0.1 mg/kg and exhibited moderate dose-dependency in
higher doses (Table 1). The greatest effect was found at 0.6 mg/kg.
Intrathecal administration of PSB-0739 displayed a dose-dependent
inhibitory effect on mechanical hyperalgesia in the range of 0.01–
0.1 mg/kg. The mED was 0.1 mg/kg (Fig. 1F, Table 1). The rank order
of mED values in the neuropathic model was the following: PSB-0739
i.t. = cangrelor N MRS2395 N clopidogrel N ticlopidine.
In the hot plate test, the baseline nociceptive threshold during two
consecutive measurements 30 min apart was 46.6 ± 0.12 °C and
46.84 ± 0.09 °C (n = 178), respectively. Intraperitoneal (i.p.) adminis-
tration ofmorphine (10 mg/kg) elicited a profound increase in the ther-
mal nociceptive threshold (50.16 ± 1.23 °C, n = 8, P b 0.05) when
compared to an identical volume of i.p. saline treatment (46.83 ±
0.53 °C, n = 8). These data are similar to literature data (Almasi et al.,
2003) and to our previous ﬁndings (Ando et al., 2010).
In this set of experiments four out of the six tested P2Y12R antagonists
exhibited signiﬁcant effect in the tested dose range (Figs. 1G–H, Table 1,
clopidogrel, ticlopidine, MRS2395, PSB0739 i.t.). The pro-drugs
clopidogrel (Fig. 1G) and ticlopidine (Table 1) exerted dose-dependent
effects and exhibited moderate potency. MRS2395 had a dose-
dependent analgesic effect within the range of 0.03–1 mg/kg with a
mED of 0.3 mg/kg (Table 1). Reactive blue 2, however, which inhibits
several P2Y receptors including P2Y12R, did not elicit signiﬁcant analgesia
in the dose-range examined (0.3–60 mg/kg, Table 1). Likewise, cangrelor,
a direct competitive non-prodrug antagonist of P2Y12Rs (0.1-1 mg/kg)
was also without signiﬁcant effect in the hot plate test (Table 1). Finally,
we have examined the potent and selective P2Y12R antagonist PSB-0739
and a signiﬁcant analgesic effect was observed at all tested doses (0.01–
0.3 mg/kg i.t.) (Fig. 1H, Table 1). Based on these data, the following
rank order of mED values was set up among the P2Y12R antagonists:
PSB-0739 i.t. N MRS2395 N clopidogrel N ticlopidine.
In vitro effects of P2Y12 receptor antagonists on the 2-methylthio-ADP
induced inhibition of cAMP formation in cells expressing recombinant
human P2Y12 receptors
Next, we examined the in vitro efﬁcacy of different antagonists puta-
tively acting at human P2Y12R: the anthraquinone dye reactive blue 2,
the structurally related anthraquinone PSB-0739, cangrelor, MRS2395
and suramin, a wide-spectrum P2 receptor antagonist (von Kügelgen,
2006) (Table 2). Clopidogrel and ticlopidine were not tested because
they are pro-drugs and therefore not suitable for in vitro testing. The
P2Y12R agonist 2-methylthio-ADP inhibited the forskolin (Fig. 2) — or
Table 2
Apparent afﬁnity values of P2Y12R antagonists determined in cells expressing the
recombinant human P2Y12R using a cAMP assay and a cAMP-dependent reporter gene
assay.
Antagonist cAMP assay Reporter gene assay
pKB/pA2* pKB/pA2*
PSB-0739 10.1 9.8*
Cangrelor 9.2# 8.6
Reactive blue 2 6.7 7.4*
Suramin 5.7* 5.5
MRS2395 Attenuation of responses at 20 μM
The * indicates a pA2 value; values determined in the reporter gene assay and values
marked with # are taken from Hoffmann et al, 2009.
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human recombinant P2Y12R. The potent reactive blue 2-derived anthra-
quinone PSB-0739 (30 nM) markedly shifted the concentration-
response curve of 2-methylthio-ADP to the right with a corresponding
apparent pKB-value of approximately 10 (Fig. 2A). PSB-0739 elicited
no change in forskolin-induced cAMP formation in CHO cells (30 nM;
Fig. 2B). Table 2 summarizes apparent afﬁnity values of antagonists at
the recombinant human P2Y12R determined with the cAMP assay and
a cAMP-dependent reporter-gene assay (Hoffmann et al., 2009). In
CHO cells expressing the human P2Y12R, reactive blue 2 (3 μM) also
shifted the concentration-response curve of 2-methylthio-ADP to the
right with an apparent pKB value of 6.7 (Fig. 2C). Reactive blue 2 in-
creased in the forskolin-induced cAMP formation by 74% (Fig. 2D). In
CHO cells expressing the human P2Y12R, MRS2395 (20 μM) attenuated
the effect of the agonist 2-methylthio-ADP (Fig. 2E); however, there
was no change in the half-maximal concentrations of the agonist in
the absence and presence of MRS2395 (amounting to 0.26 nM in both
cases; see Fig. 2E). MRS2395 (20 μM) itself markedly increased the
forskolin-induced cAMP formation in CHO cells expressing the human
P2Y12-receptor by 75% (Fig. 2F). MRS2395 (20 μM) caused a similar
increase in cellular cAMP formation induced by forskolin in mock
transfected CHO cells (Fig. 2G). Suramin was tested in 1321N1 astrocy-
toma cells stably expressing the human P2Y12R. Suramin added at
increasing concentrations of 3, 10 and 30 μM caused increasing
shifts of the concentration-response curve of 2-methylthio-ADP to the
right (Fig. 3A). Schild plot analysis revealed a pA2 value of 5.7 with a
slope (1.029) not different from unity (Fig. 3B). Suramin (30 μM) did
not change the isoprenaline-induced cAMP formation (isoprenaline
alone 34.1 ± 1.4 pmol cAMP per well, n = 47; isoprenaline plus
suramin 30 μM 37.7 ± 3.3 pmol cAMP per well, n = 17). Table 2
shows the rank order of potency of the antagonists acting at the recom-
binant human P2Y12R: PSB-0739 N cangrelor N reactive blue 2 N
suramin≈ MRS2395.
Intraplantar CFA injection elicits time-dependent upregulation of P2Y12
receptor mRNA and IL-1β protein level in rat hind paw and spinal cord
In subsequent experiments we examined the changes in the level of
mRNA transcript of the P2Y12R, using real-time RT-PCR in the rat L4-L6
spinal cord and hind paw of rats after intraplantar injection of CFA
(0.1 ml, 50%). Gene expression levels were evaluated 48 h and 96 h
after injection and were normalized against the expression level
of the 18S rRNA. Quantitative real-time PCR measurements revealed
that the P2Y12R mRNA level in the rat hind paw was upregulated by
182 ± 14% of the corresponding control values (Fig. 4A; n = 4,
P b 0.05) 48 h after the CFA treatment. The expression level of P2Y12R
in the L4-L6 spinal cord did not change in response to CFA injection at
this time point (Fig. 4B; 125± 17% of the corresponding control values;
n= 4, P N 0.05). In contrast, a signiﬁcant upregulation of P2Y12RmRNA
was detected 96 h after the CFA injection in the spinal cord, but notin the hind paw of rats, when compared to saline treated animals
(134.45 ± 6.25%, n = 4, P b 0.05 and 85.02 ± 29.2%, n = 4, P N 0.05
of the corresponding control values in the spinal cord and hind paw, re-
spectively, Figs. 4B and A).
As shown in Fig. 4C, the level of IL-1β in the saline-treated animals
48 h after the injection was 31.4 ± 4.7 pg/ml (n = 3) in the hind
paw, whereas a signiﬁcant and remarkable increase was detected 48 h
following CFA treatment (Fig. 4C, 286 ± 23 pg/ml; n = 3, P b 0.001
compared to saline). The IL-1β level in the spinal cord (L4-L6) of saline
treated rats was not signiﬁcantly different from that observed in hind
paws (Fig. 4D; 33.1±4.7 pg/ml, n=3). In addition, IL-1β protein levels
did not change in the spinal cord in response to CFA stimulation 48 h
after the injection (Fig. 4D; 39.1± 5.5 pg/ml, n=3, P N 0.05). These re-
sults suggested that there is a rapid and robust local inﬂammatory cyto-
kine response following CFA administration in the hind paw, whereas
the elevation of inﬂammatory cytokine levels in the CNS is more de-
layed. Therefore, in subsequent experiments IL-1β levels were evaluat-
ed 96 h after CFA administration in both regions. A remarkable increase
in IL-1β levelswas observed in the rat spinal cord 96h following CFA ad-
ministration when compared with the corresponding saline-treated
controls at the same time point (Fig. 4D; control: 30.6 ± 2.7 pg/ml,
CFA: 1591.6 ± 252.3 pg/ml, n = 4, P b 0.001). The elevation of IL-1β
in the hind paw was also detected at this time point when compared
to saline treated animals (Fig. 4C, control: 27.9 ± 3.5 pg/ml, n = 4,
CFA: 151.6 ± 13.3 pg/ml, n = 4, P b 0.01); however the level of IL-1β
in the hind paw was less than after 48 h CFA treatment (Fig. 4C; 48 h
CFA treatment: 286 ± 23 pg/ml, n = 4). In order to conﬁrm, whether
anti-hyperalgesic effects of P2Y12R antagonists are sustained 96 h after
CFA injection, we also evaluated mechanical hyperalgesia in saline and
drug-treated rats at this time point. Indeed, signiﬁcant analgesic effects
of both cangrelor and PSB-0739, the two most potent P2Y12R antago-
nists, were observable 96 h after CFA administration, when compared
to postoperative values of the same rats (Figs. 4E, F).
These ﬁndings indicated a time-dependent and parallel upregula-
tion of P2Y12R mRNA and inﬂammatory cytokine response in the in-
ﬂamed hind paw and spinal cord with a sustained analgesic response
of P2Y12R antagonists for up to 96 h. Therefore, in the next set of exper-
iments we evaluated the effect of cangrelor and PSB-0739 on the levels
of proinﬂammatory cytokines 48 h (hind paws) and 96 h (L4-L6 spinal
cord) after intraplantar CFA administration using a Luminex platform
assay.
P2Y12R antagonists counteract CFA-induced cytokine expression in the
lumbar spinal cord 96 h after CFA injection
In these experiments, rats were challenged with intraplantar injec-
tion of 0.1 ml CFA and cytokine levels evaluated 96 h after treatment
in the L4-L6 spinal cord. Similarly to the results of the pilot experiments,
CFA administration caused a remarkable elevation in IL-1β (Fig. 4G,
saline: 45.6 ± 1.88 pg/ml, n = 5, CFA: 203.6 ± 63.3 pg/ml, n = 5,
P b 0.001, 405% increase), however, this elevation was lower than at
measured in the hind paw after the inﬂammatory stimulus (CFA cen-
tral: 203.6 ± 63.3 pg/ml, n = 5, CFA peripheral: 11,198 ± 497 pg/ml,
n = 5). Both P2Y12R antagonists, cangrelor (3 mg/kg i.p.) and PSB-
0739 (0.3 mg/kg i.t.) completely prevented CFA-induced IL-1β produc-
tion (Fig. 4G; CFA: 203.6 ± 63.3 pg/ml, n= 5, CFA+ cangrelor: 50.4 ±
6.1 pg/ml, n = 5, P b 0.05, CFA + PSB: 49.8 ± 4.8 pg/ml, n = 5,
P b 0.05).
The TNF-α protein was undetectable in the spinal cord 96 h after in-
jection in the majority of saline- and CFA-treated animals suggesting
that constitutive expression of TNF-α proteinmight be very low in lum-
bar spinal cord regions. Basal IL-6 was also undetectable in themajority
of samples in the hind paw 48 h after saline injection. In contrast, the
level of IL-6 showed an elevation in response to 4 days of systemic
CFA treatment (Fig. 4H). Once again, cangrelor (3 mg/kg i.p.) and PSB-
0739 (0.3 mg/kg i.t.) prevented the induction of this cytokine in the
Fig. 2. Effects of P2Y12R antagonists on the inhibition of cAMP formation mediated by the agonist 2-methylthio-ADP (2-MeSADP) in cells expressing the recombinant human P2Y12R
(A, C, E) and effects of the antagonists on the cellular cAMP formation (B, D, F). cAMP formation was increased by addition of forskolin 10 μM. 2-MeSADP was added at the concentrations
indicated in the absence and presence of (A) PSB-0739 30 nM, (C) reactive blue 2 3 μMand (E)MRS2395 20 μM. (G) shows effects ofMRS2395 on the forskolin-induced cAMP formation in
mock transfected cells. Asterisks indicate signiﬁcant differences from control (con, no 2-MeSADP) (**P b 0.01, ***P b 0.001). Number signs indicate signiﬁcant differences from respective
values in the absence of an antagonist (#P b 0.05, ##P b 0.01, ###P b 0.001). One-way ANOVA followed by Tukey post-hoc test, n = 3–12/group.
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Fig. 3. Effects of the P2Y12R antagonist suramin on the inhibition of cAMP formation me-
diated by the agonist 2-methylthio-ADP (2-MeSADP) in cells expressing the recombinant
human P2Y12R (A) and Schild plot analysis (B). cAMP formationwas increased by addition
of isoprenaline 10 nM. 2-MeSADP was added at the concentrations indicated in the ab-
sence and presence of suramin used at 3, 10 and 30 μM. Asterisks indicate signiﬁcant dif-
ferences from control (-, no 2-MeSADP) (**P b 0.01). Number signs indicate signiﬁcant
differences from respective values in the absence of suramin (#P b 0.05, ##P b 0.01).
One-way ANOVA followed by Tukey post-hoc test, n = 8–45/group.
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cord was not signiﬁcantly different from that observed in rats after sa-
line injection and P2Y12R antagonists did not change the level of IL-10
after CFA stimulus (data not shown).
The effect of P2Y12R antagonists on the CFA-induced cytokine expression in
the inﬂamed hind paw of rats
In subsequent experiments, rats were challenged with intraplantar
injection of CFA (0.1 ml) or saline, as before and the cytokine response
was measured 48 h later in the inﬂamed hind paw. As shown in
Fig. 5A, the basal level of IL-1β 48 h after the saline injection was
226 ±42.3 pg/ml (n=4) in the rat hind paws. Conﬁrming the ﬁndings
obtained with the single ELISA assay, a remarkable increase in IL-1β
level was detected 48 h after intraplantar CFA treatment (11,198 ±
497 pg/ml, n = 5, P b 0.01). Systemic administration of cangrelor did
not affect the CFA-induced elevation of the level of IL-1β. In contrast, in-
trathecally injected PSB-0739 elicited a 50% decrease in the CFA-
induced IL-1β level in the hind paw (Fig. 5A).
Basal TNF-αwas undetectable in themajority of samples in the hind
paw 48 h after saline injection. In order to perform statistical analyses,
the constitutive expression of TNF-α was regarded as 10−5 pg/ml in
samples with an undetectable level of TNF-α. TNF-α protein levels
showed an increase in response to intraplantar CFA administration(47.22± 7.17 pg/ml; n= 5; P b 0.01 vs. saline) and both P2Y12R antag-
onists reduced the elevation of TNF-α levels after the inﬂammatory
stimulus (CFA + cangrelor: 26.40 ± 6.0 pg/ml, n = 5, P b 0.05,
CFA + PSB: 6.40 ± 3.4 pg/ml, n = 5, P b 0.01 vs. CFA, Fig. 5B).
A signiﬁcant increase in IL-6 concentration was also observed in
the rat hind paw 48 h following intraplantar CFA (0.1 ml) administra-
tion when compared with the corresponding saline-treated controls at
the same time point (Fig. 5C, saline: 33.5 ± 33.5 pg/ml, n = 5, CFA:
2576 ± 505.49 pg/ml, n = 5, P b 0.01). While CFA-induced IL-6 levels
were not affected by cangrelor, PSB-0739 (i.t.) alleviated the CFA-
induced increase in CFA-induced IL-6 protein levels (Fig. 5C, CFA +
PSB: 830 ± 210 pg/ml, n = 5, P b 0.05).
Among anti-inﬂammatory cytokines, we examined the changes in
the level of IL-10 in the rat hind paw 48 h after saline or CFA injection.
The basal level of IL-10 was 4.91 + 1.42 pg/ml (Fig. 5D; n = 5).
Intraplantar CFA administration caused a remarkable increase in IL-10
levels (Fig. 5D, 25.0 ± 2.88 pg/ml, n = 5, P b 0.001, 508% increase). In
the presence of cangrelor (3 mg/kg i.p.) and PSB-0739 (0.3 mg/kg i.t)
the level of IL-10 decreased after CFA injection (Fig. 5D).
These experiments showed that a marked attenuation of peripheral
cytokine response is detected at the periphery after central administra-
tion of PSB-0739 in parallel with its effect of decreasing inﬂammatory
hyperalgesia. However, PSB-0739 alone hardly penetrates the blood–
brain-barrier as it was ineffective via i.p. administration. Therefore in
the subsequent experiments an attemptwasmade to identify an efferent
pathway that mediates the inhibition of central P2Y12Rs to the peripher-
al cytokine response. At ﬁrst, chemical sympathectomy was initiated by
intraperitoneal injections of 6-OHDA in 0.1% ascorbic acid every second
day over 5 consecutive days (40 mg/kg, 60 mg/kg, 60 mg/kg). The last
6-OHDA treatmentswere followed by intraplantar injection of CFA or sa-
line as described above andmechanical hyperalgesiawasmeasured 48 h
later. To conﬁrm the depletion of noradrenaline from sympathetic nerve
terminals in response to 6-OHDA treatment in the periphery, catechol-
amine content of the hind paw was analyzed by HPLC after the
experiments (Fig. 5E). Indeed, a substantial reduction in the level of
both noradrenaline and its metabolites normetanephrine and 3,4-
dihydroxyphenylglycol (DOPEG) was observed in the hind paw in re-
sponse to 6-OHDA, when compared to saline treated rats (Fig. 5E). How-
ever, 6-OHDA treatment did not change the inhibitory effect of PSB-0739
(0.3 mg/kg i.t) on mechanical hyperalgesia evoked by intraplantar CFA
treatment (Fig. 5F).
Because electrical stimulation of the distal vagus nerve suppresses
the cytokine response in the inﬂamed hind paw (Borovikova et al.,
2000; Pavlov et al., 2003), we next tested, whether subdiaphragmatic
vagotomy relieves the effect of intrathecal application of PSB-0739 on
CFA-induced mechanical hyperalgesia. The PWT values were deter-
mined before and 10 days after the vagotomy, and they did not differ
signiﬁcantly from each other, indicating that vagotomy by itself does
not inﬂuence the mechanical sensitivity of the hind paws (38.6 ±
0.8 g, n = 10 and 37.66 ± 1.75 g, n = 10, respectively, P N 0.05).
Intraplantar CFA injection was then administered, which resulted in a
similar decline in the PWT values to that observed in naïve animals
(Fig. 5F). In vagotomized animals, however, the inhibitory effect of
PSB-0739 (0.3 mg/kg i.t) was completely absent (Fig. 5F).
Because activation ofα7nAChRs is a knownmechanism for suppres-
sion of inﬂammatory and neuropathic hypersensitivity (Loram et al.,
2012; Medhurst et al., 2008) we next examined the effect of P2Y12R an-
tagonists in the presence of the α7 nAChR antagonist MLA (3 mg/kg
i.p.), which was administered 45 min before the respective post-CFA
PWT determination. When compared to identical saline treatment,
MLA treatment alone did not change mechanical hyperalgesia
(Fig. 5F). In contrast, the antihyperalgesic effect of PSB-0739 (0.3 mg
i.t., 15 min before post-CFA measurement of mechanical hyperalgesia)
was prevented by MLA pre-treatment (Fig. 5F). The effect of MLA
pre-treatment on the inhibitory action of PSB-0739 on the induction
of IL-1β and TNF-α 48 h after CFA injection in the hind paw (Fig. 5G,
Fig. 4. Time-dependent changes of P2Y12RmRNA expression (A, B), IL-1β protein level (C, D) in the hind paw and lumbar spinal cord (L4-L6) induced by CFA; effect of P2Y12R antagonists
96 h after CFA treatment onmechanical hypersensitivity (E, F) and on central cytokine response (G, H) in rats. A, B. Changes in mRNA expression level of P2Y12 receptor in the hind paw
(A) and L4-L6 spinal cord (B). Rats received intraplantar injection of 0.1 ml 50% CFA or saline (control), and were decapitated 48 h or 96 h after treatment. Quantitative SYBR Green real-
time PCR was performed by using speciﬁc primers. The experiments were repeated two times with similar results. The expression level of the P2Y12 receptors was normalized to the ex-
pression level of the distinct housekeeping gene 18S rRNA. Data are displayed as the mean ± S.E.M. Asterisks indicate signiﬁcant differences from the corresponding control *P b 0.05,
Student's t-test. C, D. Intraplantar injection of 0.1 ml CFA caused IL-1β production in the rat hind paw (C) and spinal cord (D) in a time-dependent manner (48 or 96 h). Data are given
as the mean level of cytokines ± SEM of three independent experiments (**P b 0.01, ***P b 0.001, ns, non-signiﬁcant, Student t-test). E, F. Effects of the P2Y12R antagonist cangrelor
(E) and PSB-0739 (F) on CFA mediated inﬂammatory pain behavior 96 h after injection. The graphs show the paw withdrawal threshold values (PWT) in g corresponding to doses indi-
cated on the abscissa. Symbols indicate signiﬁcant differences from the pre-CFA treatment (***P b 0.001) and post-CFA treatment PWT values (##P b 0.01, ###P b 0.001), respectively. One-
way ANOVA followed by Neuman–Keuls post-hoc test, n= 6–12/group. G. H. Effect of P2Y12R antagonists on intraplantar CFA (0.1 ml)-induced IL-1β (G) and IL-6 (H) levels in the spinal
cord 96 h after treatment. The spinal inﬂammatory responsewas strongly inhibited by PSB-0739 (i.t.) and by systemic cangrelor administration. PSB-0739 (0.3 mg/kg) the selective P2Y12
receptor antagonist was injected i.t. 15 min prior post-CFA PWT determination, while cangrelor (3 mg/kg) the P2Y12/P2Y13 antagonist was added i.p. 30 min prior to post-CFA PWT de-
termination. The levels of cytokines were quantiﬁed in the derived supernatants by multiplex cytokine assay. Data are given as the mean level of cytokines ± SEM of 5 independent ex-
periments (*P b 0.05, **P b 0.01, ***P b 0.001, one-way ANOVA followed by Neuman–Keuls test). N.d. indicates non-detectable level, which was regarded as 10−5 pg/ml in statistical
analyses.
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Fig. 5. The effect andmechanism of action of P2Y12R antagonists on intraplantar CFA injection (0.1ml)-induced peripheral inﬂammation in rats. A, B, C. Robust elevationwere detected in the
levels of TNF-α, IL-1β and IL-6 in the hind paw 48 h after induction the inﬂammatory pain. The increase in the concentrations of cytokines was decreased by intrathecal (i.t.) PSB-0739 ad-
ministration. D. Anti-inﬂammatory cytokine response: intraplantar injection of CFA (0.1 ml) signiﬁcantly increased the level of IL-10 in the hind paw of rats 48 h after treatment. PSB-0739
(0.3 mg/kg) the selective P2Y12 receptor antagonist was injected i.t. 15min prior post-CFA PWT determination, while cangrelor (3 mg/kg) the P2Y12/P2Y13 antagonist was added i.p. 30min
prior to post-CFA PWTdetermination. The levels of cytokineswere quantiﬁed in the derived supernatants bymultiplex cytokine assay. Data are given as themean level of cytokines± SEMof
5 independent experiments (* b 0.05, ** b 0.01, *** b 0.001 one-wayANOVA followedbyNeuman–Keuls-test). E. The effect of 6-OHDApretreatment (40 mg/kg+60 mg/kg+60 mg/kg, i.p.,
in every 2nd day) on endogenousmonoamine levels in the hind paw. Control rats received saline treatment in an identical manner. The level of noradrenaline (NA), normetanephrine (NM)
and 3,4-dihydroxyphenylglycol (DOPEG) was measured by HPLC-EC and is expressed as pmol/mg protein. (*P b 0.05, Student t test with Welch correction, n = 6/group).
F. Subdiaphragmatic vagotomy (VGX) and the α7 nAChR antagonist MLA, but not 6-OHDA pretreatment occludes the antihyperalgesic effect of PSB-0739 after CFA treatment. In these ex-
periments, theα7 nACh receptor antagonistmethyllycaconitine (MLA) or its vehicle (saline, SAL)was administered 45min, while PSB-0739 (0.3 mg/kg)/saline (SAL)was injected i.t. 15min
before the post-CFA PWT determination, respectively. 6-OHDA pretreatment was performed as described in E. Vagotomywas induced after the determination of basal PWT values, and CFA
was administered 10 days after surgery (* b 0.05, ** Pb 0.01, one-wayANOVA followedbyNeuman–Keuls-test, n= 5–10/group). G, H. Theα7nAChR antagonistMLAprevents the inhibitory
effect of PSB-0739 on IL-1β (G) andTNFα (H) induction in the inﬂamed hind paw48 h following CFA treatment. Experimentswere performed according to theprotocols described in F. After
the experiments, IL-1β and TNF-α levels were quantiﬁed in the derived supernatants by multiplex cytokine assay. Data are given as the mean level of cytokines ± SEM of 5 independent
experiments. Cytokine levels are expressed as pg/ml (n = 5/group). (* b 0.05, *** P b 0.001, ns, non-signiﬁcant, one-way ANOVA followed by Neuman–Keuls-test, n = 5/group).
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B), no signiﬁcant change in either IL-1β (Fig. 5G) or TNF-α production
(Fig. 5H) was detected in rats, which received MLA pre-treatment
(3 mg/kg i.p.) prior to PSB-0739 administration (0.3 mg i.t).Accelerating rotarod test
Based on the results obtained in pain models, the effects of two of
the most potent P2Y12R antagonists, cangrelor and PSB-0739 were
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using doses effective in analgesia tests (3 mg/kg i.p. for cangrelor and
0.3 mg/kg i.t. for PSB0739, respectively), in comparison with saline
treatment using the identical route of administration. The falling latency
values of i.p. or i.t. saline-treated animals were 262.70 ± 24.90 s (n =
10) and 259.0 ± 21.23 s (n = 9) in the 300-s test period. Neither of
the two tested antagonists signiﬁcantly affected the falling latency
values (Figs. 6A, B).
Ex-vivo inhibition of ADP-induced platelet aggregation
In this test the effects of cangrelor and PSB-0739 were investigated
in their effective analgesic doses andwith identical route of administra-
tion, and their effects on the maximal aggregation of platelets induced
by ADP were evaluated.
In blood samples drawn from naive rats, ADP (5–10 μM) induced
platelet aggregation in a concentration-dependent manner (data
not shown); using 10 μM ADP, the maximal platelet aggregation was
49.5 ± 2.96% (n= 4). Similar values were obtained 30 min after intra-
peritoneal injection of saline (Fig. 6C, 45.78 ± 5.00%, n = 9, P N 0.05).
Cangrelor (3 mg/kg i.p.) signiﬁcantly reduced the maximal platelet ag-
gregation induced by ADP (Fig. 6C). In contrast, in platelets from ani-
mals treated with PSB-0739 (0.3 mg/kg) intrathecally, there was an
increase in the maximal platelet aggregation, when compared to plate-
lets from i.t. saline treated animals (Fig. 6D).
Involvement of P2Y12 receptors in the regulation of CFA-induced
inﬂammatory pain, neuropathic pain and acute thermal
nociception in mice: effect of genetic deletion of P2Y receptors
In order to further substantiate the involvement of P2Y12 receptors
in the various pain modalities described above a P2Y12R deﬁcient
mouse line was also investigated. PCR analysis of genomic DNA from
wild-type, heterozygous (P2ry12+/−), and homozygous (P2ry12−/−)
P2Y12R deﬁcient mice conﬁrmed the presence of a 541 bp length prod-
uct corresponding to the wild-type allele (GS(E)-GS(E,T)) in wild-type
mice, whereas a 404 bp length product representing the mutant alleleFig. 6.Potential side-effects of P2Y12R antagonists. A, B. The effect of cangrelor (A) and PSB-0739
the injection of cangrelor (i.p.) and expressed in s, n=10. B. PSB-0739was administered intrath
effect of cangrelor and PSB-0739 on ex vivo platelet aggregation induced by ADP (10 μM). The
(D). N = 4–9/group, **P b 0.01, Student t test. The results are expressed as percentage of max(GS(E,T)-NEO(T)) was detected in the P2ry12−/− mice (Fig. 7A). In
case of heterozygous mice both fragments were ampliﬁed (Fig. 7A).
Inmice, the baseline PWT valueswere 5.65± 0.27 g and 5.95±0.17
g in wild-type and P2ry12−/− animals, respectively; not signiﬁcantly
different from each other (n = 10, P = 0.32). Transdermal injection of
30 μL of CFA to the plantar surface of the right hind paw elicited a
marked decrease in the PWT values of the ipsilateral hind paws of
wild-type mice (Fig. 7B, multivariate ANOVA, effect of pre-post treat-
ment comparison, F1,18 = 90.24, P b 0.001). The change in mechanical
sensitivity was also signiﬁcantly different when compared to the
contralateral hind paws (ipsilateral vs. contralateral effect F1,18 =
86.06, P b 0.001, ipsilateral vs. contralateral effect x pre-post interaction,
F1,18= 55.69, P b 0.001). Themechanical hyperalgesiawas signiﬁcantly
attenuated in the P2ry12−/− animals, when compared to wild-type
mice (Fig. 7B). This interaction effect was signiﬁcant when taking
into account preoperative baseline values and contralateral hind
paws (ANOVA genotype × pre–post × ipsi-contrateral effect interaction
F1,18 = 9.16, P b 0.01).
Partial ligation of the sciatic nerve elicited a signiﬁcant decrease in
the PWT values of wild-type mice compared to either pre-operative
values (Fig. 7C, pre-operative PWT: 7.37 ± 0.22 g, n = 7, postoperative
PWT: 3.69± 0.2 g, n= 7, pre-post operative comparison F1,12 = 56.18,
P b 0.001) or to the contralateral hind paw (ipsilateral vs. contralateral
effect F1,12 = 58.31, P b 0.001, ipsilateral vs. contralateral effect × pre–
post interaction, F1,12 = 150.40, P b 0.001). Similar to the observations
in the CFA induced inﬂammatory pain model, in the absence of P2Y12
receptors, the mechanical hyperalgesia was attenuated in a slight
but signiﬁcant manner (Fig. 7C, ANOVA genotype × pre-post × ipsi-
contrateral effect interaction F1,12 = 19.81, P b 0.001).
The baseline nociceptive threshold was 42.2 ± 1.3 C in wild-type
mice (Fig. 7D). This value was elevated to 46.6 ± 0.3 °C in the
P2ry12−/−mice (n = 8, P = 0.002).
The basal IL-β level in the lumbar spinal cord of saline-treated wild-
type mice was 38.17 ± 9.98 pg/ml (n = 5, Fig. 7E). This value was in-
creased to 77.53 ± 23.47 pg/ml (P b 0.05, n = 5) 96 h following
intraplantar CFA (30 μl) injection. The IL-β level of saline treated
P2ry12−/− mice was similar to that of the wild-type mice (Fig. 7E,(B) treatment in accelerating rotarod test. A.Motor coordinationwas assessed 30min after
ecally 15minbefore testing at the dose (mg/kg) indicated on the abscissa (n=9). C, D. The
experimental animals were treated with saline (C: i.p., D: i.t.), cangrelor (C) and PSB-0739
imal aggregation (%).
Fig. 7. The effect of genetic deletion of P2Y12R in mousemodels of inﬂammatory (B), neuropathic (C) and acute pain (D). A. The identiﬁcation of wild type (+/+), heterozygote (+/−) and
homozygote p2ry12 KO genotypes by PCR based analysis.With the 3 primers used in a single reaction, an 541 bp length product was ampliﬁed for thewild type allele (GS(E)-GS(E,T)) and a
404 bp length one for the mutant allele (GS(E,T)-NEO(T)). In the case of heterozygous mice both fragments were ampliﬁed. B. Mechanical hyperalgesia before (PRE) and after (CFA)
intraplantar CFA injection in P2ry12−/− andwild-type (WT) mice. CFA (30 μl, 50% in saline) was injected into the plantar surface of the right hind paw. 48 h after treatment with CFA, me-
chanical sensitivity was measured on both hind paws. Paw withdrawal threshold values are presented in grams (mean ± S.E.M.). (***) denotes statistical signiﬁcance of P b 0.001 vs. PRE
values, (##) denotes statistical signiﬁcance of P b 0.01 between genotypes. N= 7–10/group,multivariate ANOVA, Fischer LSD post hoc test. C.Mechanical hyperalgesia in operated and sham
operated paws before (PRE) and after Seltzer operation (Seltzer) in P2ry12−/− andwild-type (WT)mice. Pawwithdrawal thresholdvalues arepresented in grams (mean± S.E.M.). (***) de-
notes statistical signiﬁcance of P b 0.001 vs. PRE values, (###) denotes statistical signiﬁcance of P b 0.001 between genotypes. N= 7/group, multivariate ANOVA, Fischer LSD post hoc test.
D. Acute thermal nocifensive threshold in P2ry12−/− and wild-type (WT) mice. PWT values are expressed in °C. ***P b 0.001 vs. WT, as indicated by the horizontal bar. N= 10/group, Stu-
dent t test. E. Basal andCFA induced IL-1β protein levels in the lumbar spinal cord of P2ry12−/− andwild-type (WT)mice 96 h after CFA/saline (SAL) treatment. IL-1β levels are expressed as
pg/ml. N = 4–5/group, *P b 0.05, two-way ANOVA, Fischer LSD post hoc test.
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production was observed in response to CFA, 96 h after the treatment
(Fig. 7E, ANOVA genotype × treatment interaction F1,34 = 42.72,
P b 0.001).
Discussion
The principal novel ﬁnding of the present study is that both pharma-
cological blockade and genetic deﬁciency of central P2Y12Rs lead to the
attenuation of inﬂammatory pain in rodents. In addition, our study con-
ﬁrms and extends previous investigations on the role of P2Y12Rs inneuropathic pain (Ando et al., 2010; Kobayashi et al., 2008;
Tozaki-Saitoh et al., 2008) and acute thermal nociception (Ando et al.,
2010). Whereas P2Y12R antagonists used in the above studies, i.e.
MRS2395, the pro-drug clopidogrel and the non-pro-drug P2Y12 recep-
tor antagonist cangrelor, have mixed or uncertain activities on human
P2Y12Rs we report here for the ﬁrst time that PSB-0739, a highly selec-
tive and potent P2Y12R antagonist (Baqi et al., 2009; Hoffmann et al.,
2009) also reproduces these effects when administered centrally.
These ﬁndings suggest that inhibition of central P2Y12Rs without action
on any other pharmacological target is sufﬁcient to elicit signiﬁcant an-
algesic effect in neuropathic and inﬂammatory pain models.
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dalities, the rank order of mED doses of the antiallodynic effects of dif-
ferent P2Y12R antagonists correlated approximately with their potency
at human P2Y12Rs (see Table 2).
There is one possible exception: MRS2395, which, showed a non-
competitive mode of antagonism in cells expressing the recombinant
human P2Y12R. In fact, MRS2395 did not elicit a rightward shift of the
concentration-response curve of the P2Y12R agonist 2-methylthio-ADP
to inhibit forskolin-induced cAMP production, but only attenuated the
maximal response to 2-methylthio-ADP (Fig. 2E). Moreover, MRS2395
alone increased the cellular cAMP formation induced by forskolin. Be-
cause this effect was also observed in mock-transfected cells and the
used cell lines display no or negligible endogenous P2Y12R expression
(Algaier et al., 2008; Erb et al., 1995; Hoffmann et al., 2008; qPCR anal-
ysis of the present study), it seems to be independent from P2Y12R. Re-
active blue 2 also increased cAMP levels, but in contrast to MRS2395,
reactive blue 2 clearly shifted the concentration–response-curve of the
agonist 2-methylthio-ADP to the right. MRS2395 was originally pre-
sumed to be P2Y12R antagonist, because it attenuated ADP-induced
platelet aggregation, but did not antagonize P2Y1 receptor-mediated re-
sponses (Xu et al., 2002). The present data indicate a non-competitive
mode of antagonistic action of MRS2395 on hP2Y12R. A portion of that
antagonistic effect of MRS2395 may be mediated indirectly by an effect
on cellular cAMP concentrations. Interestingly, not all P2Y12R antago-
nists reproduced the effect of genetic deletion and their effect depended
on the speciﬁc experimental model. In the hot plate test, clopidogrel,
ticlopidine,MRS2395 and PSB-0739 elicited signiﬁcant analgesic effects,
whereas cangrelor and reactive blue 2 remained ineffective in doses
that produced signiﬁcant antihyperalgesic effects in the CFAmodel. Re-
active blue 2 was also ineffective in the tested range in the neuropathic
pain model. A potential explanation to this discrepancy is that, in con-
trast to PSB-0739, cangrelor and reactive blue 2 also inhibit the P2Y13 re-
ceptor in addition to P2Y12R (cf. von Kügelgen, 2006), which may
confound the effect. Previously, we found that activation of P2Y13R,
but not P2Y12Rs inhibits the stimulation-evoked release of glutamate
from acute spinal cord slices (Heinrich et al., 2008), indicating that the
activation, but not the inhibition of the P2Y13 receptor conveys acute
antinociceptive action in the spinal cord.
As a conﬁrmation of the ﬁndings obtained on rats, we also report
here that mice genetically deﬁcient in P2Y12R display elevated baseline
nociceptive threshold, and attenuated mechanical hyperalgesia in the
respective neuropathic and inﬂammatory pain models. Although het-
erozygous mice were not assessed in this study previous studies re-
vealed that the phenotype of P2ry12+/− mice was either similar to
wild-type or transitional between P2ry12+/+ and P2ry12−/−mice, de-
pending on the experimental conditions (André et al., 2003). For in-
stance, partly relevant to our conditions, in the case of in vitro platelet
aggregation and inhibition of cAMP production by ADP, the values of
heterozygotes were closed to the wild-type, while they displayed a sig-
niﬁcantly elongated blood vessel occlusion time in vivo.
Next, we have attempted to identify the mechanism of action of
P2Y12R antagonists for alleviating CFA-induced mechanical hyperalgesia
in rats. Previous studies indicated an upregulation of P2Y12R mRNA in
microglia cells of the spinal cord in neuropathic models using either
semi-quantitative RT-PCR (Kobayashi et al., 2008) or in situ hybridiza-
tion histochemistry (Kobayashi et al., 2008, 2012). In our experiments,
a massive upregulation of P2Y12R mRNA was detected 48 h after CFA
injection in the hind paw in parallel with the robust induction of the pro-
inﬂammatory cytokine IL-1β, indicating a rapid cytokine response at the
periphery. Interestingly, however, neither P2Y12R mRNA expression nor
IL-1β production was changed signiﬁcantly at this time point in the spi-
nal cord, only later, suggesting a time-dependent reactivity of P2Y12R-
mediated events locally and at a distance from the site of inﬂammation.
Indeed, a profound elevation of IL-1β productionwas detected 96 h after
CFA injection in the spinal cord, coincidently with the upregulation of
P2Y12R mRNA and the sustained antihyperalgesic response of bothcangrelor and PSB-0739. Both P2Y12R antagonists almost completely
abolished the elevation of IL-1β protein levels in response to CFA appli-
cation in the spinal cord. These ﬁndings were also conﬁrmed by using
P2Y12R-deﬁcient mice, in which no increase in IL-1β production was de-
tected in response to CFA treatment. IL-1β is regarded as a mediator of
central sensitization mechanisms leading to enhanced pain sensitivity
by the augmentation of spontaneous miniature excitatory postsynaptic
currents (sEPSCs) with a simultaneous inhibition of spontaneous
miniature inhibitory postsynaptic currents (sIPSCs) in Lamina II neurons
of spinal cord slices and by the induction of CREB phosphorylation
and subsequent long-term plasticity events in spinal nociceptive
neurons (Kawasaki et al., 2008). Therefore, the inhibition of spinal
IL-1β production is one potential signaling pathway that mediates the
antihyperalgesic action of P2Y12R antagonists in inﬂammatory pain.
However, it is probably not the only one, as P2Y12R antagonists were al-
ready effective in the alleviation of CFA-induced inﬂammatory pain 48 h
after CFA injection, i.e. before the induction of IL-1β in the spinal cord.
Moreover, we detected the profound induction of proinﬂammatory
cytokines at the periphery, i.e. in the inﬂamed hind paw at this time
point, and PSB-0739 effectively counteracted the elevation of IL-1β,
TNF-α and IL-6. The contribution of peripheral cytokines to the pain
sensitization is well documented (Ren and Dubner, 2010; Scholz and
Woolf, 2007); therefore it is reasonable to suggest that peripheral IL-
1β, TNF-α and IL-6 mediate the antihyperalgesic action of PSB-0739 at
this time point. Upregulation of P2Y12Rs in the hind paw, detected in
our study may contribute to this action. P2Y12R is expressed not only
on the peripheral sensory nerve terminals (Malin and Molliver, 2010),
but also probably elsewhere as well, such as on keratinocytes and den-
dritic cells, which also participate in cutaneous-neuro-immune interac-
tions and known to express various other subtypes of P2 receptors
(Dussor et al., 2009). Nevertheless, the mechanism leading from central
administration of PSB-0739 to the alleviation of peripheral cytokine re-
sponse still requires explanation. Although we cannot entirely exclude
the possibility that the compound itself reached the periphery,
increased permeability of the blood–brain barrier is observable only
3–5 days after CFA administration (Raghavendra et al., 2004), and the
same dose of PSB-0739 was ineffective when administered intraperito-
neally, which suggests a primary central target site of its action. A poten-
tial efferent neuronal pathway would be sympathetic postganglionic
nerves originating in the lumbar spinal cord (Sandkühler, 2009),
which express P2Y12R (Lechner et al., 2004). 6-OHDA pretreatment,
however did not counteract the effect of PSB-0739 in alleviating inﬂam-
matory hyperalgesia. In contrast, following subdiaphragmatic vagotomy
or systemic treatmentwith theα7 nAChR antagonistMLA, PSB-0379 no
longer inﬂuenced mechanical hypersensitivity and the peripheral cyto-
kine response. Because the penetration of systemic MLA to the CNS is
negligible (Medhurst et al., 2008; Turek et al., 1995), these ﬁndings sug-
gest that the vagus nervemediates this effect from the spinal cord to the
periphery with the involvement of α7 nAChRs. This is consistent with
the inhibitory effect of the distal vagus nerve, on the cytokine response
in the inﬂamed hind paw (Borovikova et al., 2000; Pavlov et al., 2003)
and with the presence of α7 nAChRs on peripheral immune cells. The
activation of α7 nAChRs is a well-documented mechanism for the sup-
pression of inﬂammatory and neuropathic pain (Loram et al., 2012;
Medhurst et al., 2008). It was assumed, therefore, that endogenous acti-
vation of α7 nAChRs on immune cells recruited at the site of inﬂamma-
tion would be responsible for this effect. However, early mediators of
the inﬂammatory response, such as different chemokines or other, yet
unidentiﬁed supraspinal mechanisms might also participate in the ef-
fect of central P2Y12R on the local peripheral cytokine response at this
time point (Kiguchi et al., 2012; Ransohoff, 2009). Previous ﬁndings,
showing that activation of P2Y12R is involved in the chemotaxis of mi-
croglia (Honda et al., 2001) as well as in the engulfment of nerve
axons by microglia (Maeda et al., 2010) also point in this direction.
A major limitation of the current therapy used in inﬂammatory and
neuropathic pain is not only the lack of efﬁcacy but also the occurrence
177G. Horváth et al. / Neurobiology of Disease 70 (2014) 162–178of untoward side-effects in the therapeutic dose-range (Negus et al.,
2006). Importantly, using doses higher than the mED of the respective
compounds, we did not detect any acute effect on motor coordination
by the most potent P2Y12R antagonists used in the study. On the other
hand, i.p. application of an analgesic dose of cangrelor, but not i.t. appli-
cation of PSB-0739 had a signiﬁcant inhibitory effect on ex vivo platelet
aggregation, which is unsurprising considering the well-known inhibi-
tory effects of P2Y12R antagonists on this process (Schumacher et al.,
2007). This effect, however, could also be equally considered as a pro-
tective effect on cardiovascular risk rather than a side effect, given that
the P2Y12R occupancy in the blood shows close correlationwith the for-
mation of arterial thrombi. The ﬁnding that PSB-0739 did not inhibit but
augmented platelet aggregation indicates that the analgesic effect of
P2Y12R antagonists could be enhanced by the adequate penetration
into the CNS without increasing the risk of bleeding.
In conclusion, our ﬁndings provide a rationale to target central
P2Y12Rs as a potential therapeutic approach in inﬂammatory and neu-
ropathic pain.
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